Spectral AI Secures $31.7M BARDA Advance, Reports Strong Clinical Data & Improved Liquidity

summarizeSummary

Spectral AI announced a $31.7 million non-dilutive funding advance from BARDA and positive clinical trial results for its DeepView System, significantly boosting its financial runway and commercialization prospects, despite reporting material weaknesses in internal controls.

check_boxKey Events

• Secures $31.7M BARDA Funding Advance

  As a subsequent event on March 18, 2026, Spectral AI received a contract modification from BARDA for a $31.7 million advance from its existing $150 million contract, including a no-cost extension and acceleration of the next phase. The company committed $9.7 million to these development costs.

• Positive Clinical Validation for FDA De Novo Submission

  The DeepView System's validation study for FDA De Novo submission demonstrated superiority in sensitivity and met non-inferiority in specificity compared to clinician assessment, a critical milestone for U.S. market authorization.

• Improved Liquidity Position

  Cash and cash equivalents increased to $15.4 million by December 31, 2025, up from $5.2 million in 2024. Management believes this, combined with the BARDA contract and other financings, provides sufficient working capital for at least one year.

• Material Weaknesses in Internal Controls Identified

  The company identified material weaknesses in internal control over financial reporting related to complex equity arrangements, financial statement close processes, and accruals/unbilled revenue, with remediation efforts underway.

auto_awesomeAnalysis

Spectral AI's annual report highlights a significant non-dilutive funding advance of $31.7 million from BARDA, announced as a subsequent event on March 18, 2026. This funding, part of an existing $150 million contract, includes a no-cost extension and acceleration of the next phase, providing crucial capital and validating the company's technology. The company also reported successful clinical validation for its DeepView System's FDA De Novo submission, showing superiority in sensitivity and non-inferiority in specificity compared to clinician assessment, a key step towards commercialization. The cash balance significantly increased to $15.4 million by year-end 2025, and management projects sufficient liquidity for at least one year. However, the company identified material weaknesses in internal control over financial reporting, though remediation efforts are ongoing. Despite continued operating losses, the substantial non-dilutive funding and positive clinical data significantly de-risk the company's path to market.